Genoss begins China approval process for new HA filler

Medical device company Genoss has announced the commencement of the product approval process in China for its new hyaluronic acid (HA) filler, High Elastic. This move signifies the company's strategic effort to broaden its presence in the significant Chinese aesthetic market.

Genoss currently supplies two types of its Vmonalisa HA fillers to international markets. The High Elastic HA filler, developed to meet specific treatment purposes and clinical demands, has completed its clinical trials. Upon receiving approval from China's National Medical Products Administration (NMPA), Genoss will offer a total of four HA filler products in China, combining the existing Vmonalisa line with the new High Elastic range.

“

Global medical professional exchanges are a process of confirming clinical demand and market conditions in various countries.

The company has been actively engaging with local medical professionals, recently visiting the Wonderland Plastic Surgery Hospital in Hangzhou. These interactions are crucial for Genoss to understand the latest trends in aesthetic medicine, gather clinical feedback, and identify specific market needs. This feedback loop is integral to their research and development process, ensuring that future products align with the evolving demands of different national markets.

A Genoss representative emphasized the importance of global medical professional exchanges, stating, "Global medical professional exchanges are a process of confirming clinical demand and market conditions in various countries." The company is committed to reflecting the gathered clinical experiences and opinions in its R&D efforts and ensuring the smooth progression of the ongoing product approval procedures.

“

We will reflect the gathered clinical experiences and opinions in our research and development and proceed with the product approval process without any setbacks.